. American-psychiatric-association, Diagnostic and statistical manual of mental disorders American Psychiatric Association, 2000.

P. Nr, . R-i-c-ed, and E. Stadlan, F o l s t e i nM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, vol.34, pp.939-983, 1984.

H. Braak and E. Braak, Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories, Neurobiology of Aging, vol.18, issue.4, pp.351-358, 1997.
DOI : 10.1016/S0197-4580(97)00056-0

A. Delacourte, J. David, N. Sergeant, L. Buee, A. Wattez et al., The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease, Neurology, vol.52, issue.6, pp.1158-65, 1999.
DOI : 10.1212/WNL.52.6.1158

B. Dubois, H. Feldman, C. Jacova, S. Dekosky, P. Barberger-gateau et al., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS???ADRDA criteria, The Lancet Neurology, vol.6, issue.8, pp.734-780, 2007.
DOI : 10.1016/S1474-4422(07)70178-3

M. Albert, S. Dekosky, D. Dickson, B. Dubois, H. Feldman et al., The diagnosis of mild cognitive impairment due to Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer???s Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.270-279, 2011.
DOI : 10.1016/j.jalz.2011.03.008

W. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist et al., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Annals of Neurology, vol.107, issue.suppl 1, pp.306-325, 2004.
DOI : 10.1002/ana.20009

A. Forsberg, H. Engler, O. Almkvist, G. Blomquist, G. Hagman et al., PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiology of Aging, vol.29, issue.10, pp.1456-65, 2008.
DOI : 10.1016/j.neurobiolaging.2007.03.029

J. Rinne, D. Brooks, M. Rossor, N. Fox, R. Bullock et al., 11C-PiB PET assessment of change in fibrillar amyloid-?? load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study, The Lancet Neurology, vol.9, issue.4, pp.363-72, 2010.
DOI : 10.1016/S1474-4422(10)70043-0

M. Mintun, G. Larossa, Y. Sheline, C. Dence, S. Lee et al., [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease, Neurology, vol.67, issue.3, pp.446-52, 2006.
DOI : 10.1212/01.wnl.0000228230.26044.a4

W. Jagust, S. Landau, L. Shaw, J. Trojanowski, R. Koeppe et al., Relationships between biomarkers in aging and dementia, Neurology, vol.73, issue.15, pp.1193-1202, 2009.
DOI : 10.1212/WNL.0b013e3181bc010c

Y. Kudo, N. Okamura, S. Furumoto, M. Tashiro, K. Furukawa et al., 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients, Journal of Nuclear Medicine, vol.48, issue.4, pp.553-61, 2007.
DOI : 10.2967/jnumed.106.037556

M. Waragai, N. Okamura, K. Furukawa, M. Tashiro, S. Furumoto et al., Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease, Journal of the Neurological Sciences, vol.285, issue.1-2, pp.100-108, 2009.
DOI : 10.1016/j.jns.2009.06.005

H. Shao, N. Okamura, K. Sugi, S. Furumoto, K. Furukawa et al., Voxel-Based Analysis of Amyloid Positron Emission Tomography Probe [11C]BF-227 Uptake in Mild Cognitive Impairment and Alzheimer???s Disease, Dementia and Geriatric Cognitive Disorders, vol.30, issue.2, pp.101-112, 2010.
DOI : 10.1159/000318754

G. Small, V. Kepe, L. Ercoli, P. Siddarth, S. Bookheimer et al., PET of Brain Amyloid and Tau in Mild Cognitive Impairment, New England Journal of Medicine, vol.355, issue.25, pp.2652-63, 2006.
DOI : 10.1056/NEJMoa054625

P. Thompson, L. Ye, J. Morgenstern, L. Sue, T. Beach et al., Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer???s disease pathologies, Journal of Neurochemistry, vol.57, issue.2, pp.623-653, 2009.
DOI : 10.1111/j.1471-4159.2009.05996.x

R. Vandenberghe, K. Van-laere, A. Ivanoiu, E. Salmon, C. Bastin et al., F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial, Annals of Neurology, vol.9, issue.3, pp.319-348, 2010.
DOI : 10.1002/ana.22068

C. Rowe, U. Ackerman, W. Browne, R. Mulligan, K. Pike et al., Imaging of amyloid ?? in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism, The Lancet Neurology, vol.7, issue.2, pp.129-164, 2008.
DOI : 10.1016/S1474-4422(08)70001-2

H. Barthel, H. Gertz, S. Dresel, O. Peters, P. Bartenstein et al., Cerebral amyloid-?? PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study, The Lancet Neurology, vol.10, issue.5, pp.424-459, 2011.
DOI : 10.1016/S1474-4422(11)70077-1

C. Jr, A. Pontecorvo, M. Hefti, F. Skovronsky, and D. , The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience, Q J Nucl Med Mol Imaging, vol.53, pp.387-93, 2009.

S. Choi, G. Golding, Z. Zhuang, W. Zhang, N. Lim et al., Preclinical Properties of 18F-AV-45: A PET Agent for A?? Plaques in the Brain, Journal of Nuclear Medicine, vol.50, issue.11, pp.1887-94, 2009.
DOI : 10.2967/jnumed.109.065284

C. Clark, J. Schneider, B. Bedell, T. Beach, W. Bilker et al., Use of Florbetapir-PET for Imaging ??-Amyloid Pathology, JAMA, vol.305, issue.3, pp.275-83, 2011.
DOI : 10.1001/jama.2010.2008

K. Lin, W. Hsu, I. Hsiao, S. Wey, L. Jin et al., Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent ??? a pilot study, Nuclear Medicine and Biology, vol.37, issue.4, pp.497-508, 2010.
DOI : 10.1016/j.nucmedbio.2010.02.003

D. Wong, P. Rosenberg, Y. Zhou, A. Kumar, V. Raymont et al., In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18), Journal of Nuclear Medicine, vol.51, issue.6, pp.913-933, 2010.
DOI : 10.2967/jnumed.109.069088

A. Fleisher, K. Chen, X. Liu, A. Roontiva, P. Thiyyagura et al., Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease, Archives of Neurology, vol.68, issue.11, pp.1404-1415, 2011.
DOI : 10.1001/archneurol.2011.150

R. Petersen, G. Smith, S. Waring, R. Ivnik, E. Tangalos et al., Mild Cognitive Impairment, Archives of Neurology, vol.56, issue.3, pp.303-311, 1999.
DOI : 10.1001/archneur.56.3.303
URL : https://hal.archives-ouvertes.fr/inserm-00112038

M. Sarazin, C. Berr, D. Rotrou, J. Fabrigoule, C. Pasquier et al., Amnestic syndrome of the medial temporal type identifies prodromal AD: A longitudinal study, Neurology, vol.69, issue.19, pp.1859-67, 2007.
DOI : 10.1212/01.wnl.0000279336.36610.f7
URL : https://hal.archives-ouvertes.fr/inserm-00169640

S. Mattis, Mental status examination for organic mental syndrome in the elderly patient, Geriatric psychiatry, pp.77-121, 1976.

E. Grober, H. Buschke, H. Crystal, S. Bang, and R. Dresner, Screening for dementia by memory testing, Neurology, vol.38, issue.6, pp.900-903, 1988.
DOI : 10.1212/WNL.38.6.900

G. Deloche, D. Hannequin, M. Dordain, D. Perrier, B. Pichard et al., Picture Confrontation Oral Naming: Performance Differences between Aphasics and Normals, Brain and Language, vol.53, issue.1, pp.105-125, 1996.
DOI : 10.1006/brln.1996.0039

C. Golden, T. Hammeke, and A. Purisch, Diagnostic validity of a standardized neuropsychological battery derived from Luria's Neuropsychological Tests., Journal of Consulting and Clinical Psychology, vol.46, issue.6, pp.1258-65, 1978.
DOI : 10.1037/0022-006X.46.6.1258

F. Mahieux-laurent, C. Fabre, E. Galbrun, A. Dubrulle, and C. Moroni, Validation d???une batterie br??ve d?????valuation des praxies gestuelles pour consultation M??moire. ??valuation chez 419 t??moins, 127 patients atteints de troubles cognitifs l??gers et 320 patients atteints d???une d??mence, Revue Neurologique, vol.165, issue.6-7, pp.560-567, 2009.
DOI : 10.1016/j.neurol.2008.11.016

A. Rey, Manuel: test de copie et de reproduction de mémoire de figures géométriques complexes. Paris: Centre de Psychologie Appliquée, 1959.

A. Jensen, Scoring the Stroop test, Acta Psychologica, vol.24, pp.398-408, 1965.
DOI : 10.1016/0001-6918(65)90024-7

D. Wechsler, Wechsler Memory Scale Revised manual. San Antonio: The Psychological Corporation, 1987.

R. Reitan, VALIDITY OF THE TRAIL MAKING TEST AS AN INDICATOR OF ORGANIC BRAIN DAMAGE, Perceptual and Motor Skills, vol.19, issue.3, pp.271-277, 1958.
DOI : 10.2466/pms.1958.8.3.271

Y. Liu, L. Zhu, K. Plössl, S. Choi, H. Qiao et al., Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease, Nuclear Medicine and Biology, vol.37, issue.8, pp.917-942, 2010.
DOI : 10.1016/j.nucmedbio.2010.05.001

R. Development-core-team, W. Klunk, E. Abrahamson, C. Mathis, J. Price et al., R: A language and environment for statistical computing. R Foundation for Statistical Computing ISBN 3-900051-07-0. URL http Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease, Brain, vol.131, pp.1630-1675, 2008.

C. Raji, J. Becker, N. Tsopelas, J. Price, C. Mathis et al., Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B, Journal of Neuroscience Methods, vol.172, issue.2, pp.277-82, 2008.
DOI : 10.1016/j.jneumeth.2008.05.005

C. Rowe, S. Ng, U. Ackermann, S. Gong, K. Pike et al., Imaging ??-amyloid burden in aging and dementia, Neurology, vol.68, issue.20, pp.1718-1743, 2007.
DOI : 10.1212/01.wnl.0000261919.22630.ea

V. Villemagne, K. Ong, R. Mulligan, G. Holl, S. Pejoska et al., Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias, Journal of Nuclear Medicine, vol.52, issue.8, pp.1210-1217, 2011.
DOI : 10.2967/jnumed.111.089730

G. Halliday, Y. Song, and A. Harding, Striatal ??-amyloid in dementia with Lewy bodies but not Parkinson???s disease, Journal of Neural Transmission, vol.65, issue.12, pp.713-722, 2011.
DOI : 10.1007/s00702-011-0641-6

J. Koivunen, A. Verkkoniemi, S. Aalto, A. Paetau, J. Ahonen et al., PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease, Brain, vol.131, issue.7, pp.1845-53, 2008.
DOI : 10.1093/brain/awn107

K. Furukawa, N. Okamura, M. Tashiro, M. Waragai, S. Furumoto et al., Amyloid PET in mild cognitive impairment and Alzheimer???s disease with BF-227: comparison to FDG???PET, Journal of Neurology, vol.355, issue.5, pp.721-728, 2010.
DOI : 10.1007/s00415-009-5396-8

E. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu et al., Fibrillar amyloid-?? burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease, Proceedings of the National Academy of Sciences, vol.106, issue.16, pp.6820-6825, 2009.
DOI : 10.1073/pnas.0900345106

T. Grimmer, S. Tholen, B. Yousefi, P. Alexopoulos, A. Forschler et al., Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ??4 Genotype in Alzheimer's Disease, Biological Psychiatry, vol.68, issue.10, pp.879-84, 2010.
DOI : 10.1016/j.biopsych.2010.05.013